Drug
INO 1001 clinical trials
Also written INO-1001.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
- INO-1001
- 3
Studies by the year they started
3 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Inotek Pharmaceuticals Corporation (2) · Genentech, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses INO 1001 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung BypassTerminatedPhase 2Inotek Pharmaceuticals CorporationNCT00271167Written as INO-1001
- A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With MelanomaTerminatedPhase 1Genentech, Inc.NCT00272415Written as INO-1001
- A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary InterventionCompletedPhase 2Inotek Pharmaceuticals CorporationNCT00271765Written as INO-1001
Codes
What other systems call INO 1001 · ClinicalTrials.gg INT004699
- UNII (FDA) 55E08EN074INO-1001One source FDA
- NCI Thesaurus C61315INO-1001One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 55E08EN074 | INO-1001 | One source FDA |
| NCI Thesaurus | C61315 | INO-1001 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.